Member Info for EXMEX

Thanks Wilson ,their linkedin site gives a bit more info on what they do.

Someone at Novacyt likes this company. They help medtech companies to secure regulatory approvals and/or conduct clinical studies in India, Europe, United States and Asia-Pacific countries.
http://www.8chealth.com/

How many q16, q32, Mygo Pro and Mygo Mini's did they manufacture in the eleven week's from the October takeover to 2020 year end ? Revenue for this period was £6.9 million, of which £5.8 million was inter company sales and £1.1 million direct sales to customers.The latter would most likely be sales of the Mygo devices and reagents. Although we don't know the ratio of which device's were manufactured you could be looking at an estimate of between 650 and 750 unit's in total going off what prices we know.
From the year end accounts it shows that It-Is took out a lease on extra workspace at nearby Pulrose House in September and then in December they took out a three year lease on MMC house on the same road . How long will it be till they outgrow these premises
https://www.realla.co.uk/details/21486038

From the investor presentation we learnt that PROmate was initially developed for covid testing in decentralised and close patient settings.These new technologies are now being developed to be used in other diagnostic application's ( 16 minutes into presentation ).
Then we were told assays are being developed to test for FluA, FluB and RSV to be used in poc settings and laboratories .Are these using the PROmate chemistry?
Novacyt also mentioned they are developing test's targeted at transplant surgery testing .If I'm correct these are Cytomegalovirus, Epstein Barr Syndrome and B K Virus. Will these be simplified immuno assays?

Try again
https://www.biofortuna.com/portfolio_item/lyophilisation-of-point-of-care-poc-ivd-qpcr-assay-and-controls

Try this one
https://www.biofortuna.com/portfolio_item/lyophilisation-of-care-poc-ivd-qpcr-assay-and-controls/

Wilson63, did you read the case study regarding lyophilisation-of-point-of-care-poc-ivd-qpcr-asssay on the Biofortuna website ?

Pierrick, resolution six from last year's AGM gave the company the authority to buy back up to 200,000 euro's worth of their shares up to a maximum share price of 12 euro's. Previously this was set at 100,000 and 8 euro's in the Aim admission document. The liquidity arrangement comes under the umbrella of this resolution.

mavs, from what I can see Israel has started the mass testing of school children before they start back next wednesday after the summer holidays. It looks like these test's are finding plenty of additional cases.
https://www.timesofisrael.com/israel-hits-new-record-daily-covid-cases-with-testing-high-ahead-of-school-year/

From the presentation we learnt that the PROmate chemistry could also be applied to the Winterplex and other respiratory disease test's. Rewind five month's and Novacyt were busy recruiting additional scientists whose job remit said they would be working on new assays and redeveloping existing ones . In time we could possibly see a good menu of PROmate based test's.
We were also told that Novacyt have run 15 clinical trial's since Q4 2020 in the UK and overseas and this expertise can also be used to evaluate a potential m+a target.
In the question's and answer's section of the meeting GM said that Novacyt would be updating the market in the near future about their plan's in the USA and this could also be accompanied by another investor presentation.
Plenty of info provided at the last presentation, just needs more than one listen to pick up on everything.

I see Biofortuna put out a big teaser on twitter last thursday, seems like they are expanding.

The UK government brought out new legislation last summer to protect UK companies playing a role in fighting the pandemic from take over by overseas business's.
https://www.pinsentmasons.com/out-law/news/takeovers-uk-rules-foreign-investment

When does that black box ( automated sample prep ) get launched? Pictured 17 minutes into the investor presentation.

I took a look at the list of rapid covid19 antigen test's that have been validated by MHRA. Currently there are 36 test's that have been approved. Of these ,19 are from Chinese manufacturers ,whilst just 6 are from UK manufacturers. So under the new guidance ( must be UK manufactured ) does that just leave 6 test's that are presently eligible.

Where did the post's about the updated standards for lateral flow test's go ? Seems there's been a cull.
Isn't tomorrow the last day of the Innova eul extention.

https://leamingtonobserver.co.uk/news/massive-fire-raging-in-leamington-near-covid-19-testing-megalab-31851/

https://Leamington observer.co.uk/news/massive-fire-raging-in-leamington-near -covid-19-testing-megalab-31851/

It's been reported today that a new sublineage of the Delta variant has been discovered , now named AY.12. Apparently this is responsible for 51% of the cases in Israel . Could this account for the decline in vaccine efficacy in Israel ?This might be one of the reason's for a delay in booster jabs if it's still the original delta variant that's dominant in the UK.

As the delta variant surges through the USA hospitals in the worst hit areas are seeing a big increase in the number of children needing treatment.
https://www.nbcnews.com/news/us-news/child-covid-19-hospitalizations-new-high-august-n1277119

ChasPB,the Patent Box tax relief was first mentioned twelve month's ago in the previous year end report .At the time Novacyt quoted a possible tax rate of around 12% on newly developed and patented product's . Last time I looked Novacyt had over twenty patent applications pending.If successful you could have a significant saving in tax payment's.As far as I know it can be backdated to when the patent application was put in.